Company Filing History:

26 out of 677

Eisai Company, Limited

patents

2 out of 527

Eisai R&d Management Co., Ltd.

patents

Years Active: 1981-2010

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7772226 - Condensed imidazole derivatives (2010-08-10),

2. 7238720 - Pharmaceutical use of N-carbamoylazole derivatives (2007-07-03),

3. 7112593 - N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient (2006-09-26),

4. 7074798 - Xanthine derivative and DPPIV inhibitor (2006-07-11),

5. 6599917 - Quinuclidine compounds and drugs containing the same as the active ingredient (2003-07-29),

6. 5801180 - Quinazoline derivatives (1998-09-01),

7. 5719303 - Phosphonic acid derivatives (1998-02-17),

8. 5716993 - Anthranilic acid derivatives (1998-02-10),

9. 5693652 - Benzimidazoles for ischemic heart conditions (1997-12-02),

10. 5668136 - Trisubstituted benzene derivatives, composition and methods of treatment (1997-09-16),

11. 5576322 - Anti-ischemic 2,4-diaminoquinazolines (1996-11-19),

12. 5453524 - Phosphorus-containing isoprenoid derivatives (1995-09-26),

13. 5206403 - Diphenylethylene derivatives, pharmaceutical compositions containing (1993-04-27),

14. 5182301 - Diphenylethylene derivatives pharmaceutical compositions containing same (1993-01-26),

15. 5103010 - Diphenylethylene derivatives, pharmaceutical compositions containing (1992-04-07),

Title: Hironori Ikuta: Innovator in Pharmaceutical Compounds

Introduction: Hironori Ikuta is a prominent inventor based in Ushiku, Japan, known for his significant contributions to the pharmaceutical field with a total of 28 patents. His work primarily focuses on novel compounds that offer innovative solutions in medical science, particularly in the area of DPPIV inhibition.

Latest Patents: Two of Hironori Ikuta's latest patents exemplify his expertise and dedication to pharmaceutical innovation. The first patent involves "Condensed Imidazole Derivatives," which are described as novel compounds exhibiting excellent DPPIV-inhibiting activity. The second patent revolves around the "Pharmaceutical Use of N-Carbamoylazole Derivatives," detailing the usefulness of 1-carbamoylazole derivatives as medicaments and highlighting their effectiveness as dipeptidyl peptidase IV inhibiting agents. These innovations are essential for developing new therapeutic agents.

Career Highlights: Hironori Ikuta has had a distinguished career, having worked for respected organizations in the pharmaceutical industry. Notably, he has been associated with Eisai Company, Limited, and Eisai R&D Management Co., Ltd. His work in these organizations has significantly impacted the research and development of innovative pharmaceutical products.

Collaborations: Throughout his career, Hironori Ikuta has collaborated with several talented individuals, including Kenji Hayashi and Shinya Abe. These professional partnerships have enhanced his research endeavors and contributed to delivering breakthrough inventions in the pharmaceutical landscape.

Conclusion: Hironori Ikuta stands out as an innovative inventor committed to advancing pharmaceutical science. With his impressive portfolio of patents and collaborative efforts, he continues to make noteworthy contributions that benefit the medical community and the world at large. His dedication to discovering novel compounds holds promise for future therapeutic developments.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.